ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0399

Eosinophilia and Exposure to IL-1 and IL-6 Blocking Biologic Medications in a Systemic Juvenile Idiopathic Arthritis Patient Cohort

Rachel Dickey1, Doel Dhar2, Srushti Gangireddy3, Henry H. Ong3, Wei-Qi Wei3 and Anna Patrick3, 1Lipscomb University College of Pharmacy, Athens, TN, 2Monroe Carell Jr Children's Hospital at Vanderbilt, Nashville, TN, 3Vanderbilt University Medical Center, Nashville, TN

Meeting: ACR Convergence 2024

Keywords: Biologicals, Juvenile idiopathic arthritis, Pediatric rheumatology, Still's disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Pediatric Rheumatology – Clinical Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is a severe disease with symptoms of fevers, rash, and arthritis. High levels of the inflammatory cytokines interlukin-1 (IL-1) and interlukin-6 (IL-6) contribute to the systemic features. In SJIA, IL-1 and IL-6 blocking biologics are lifesaving medications, yet data suggests these medications may have an association with eosinophilia and severe drug reactions. In this study, we sought to clarify the relationships between eosinophilia and IL-1 and IL-6 blocking biologic medications using an electronic health record (EHR) derived SJIA cohort.

Methods: SJIA patient charts were identified using JIA and adult-onset Still’s disease associated ICD-9 and ICD-10-CM codes (Table 1). Manual review identified charts with inclusion criteria of ≥ 2 rheumatology encounters documenting SJIA and symptom onset ≤ 16 years old. Manual review identified clinical documentation at time of SJIA diagnosis. Demographic, medication, laboratory, and ICD code data were extracted. The first SJIA-associated ICD code approximated the first encounter for SJIA. Eosinophilia was defined as an absolute eosinophil count ≥ 500 cells/microliter. An eosinophilia cluster was defined as eosinophilia within a three-month timespan. IL-1 blocking biologics (anakinra, canakinumab) and IL-6 blocking biologic (tocilizumab) exposure was determined by prescribing data. Statistical analysis was performed by Mann-Whitney and Fisher’s exact testing.

Results: We identified 163 SJIA patients (Table 2). An eosinophilia cluster occurred in 77 patients (47%), with 32 patients (20%) having multiple eosinophilia clusters. Exposure to IL-1 or IL-6 blocking medications occurred in 106 patients (65%) of which 54 (33%) also had eosinophilia.

Clinical documentation was available at the time of SJIA diagnosis for 107 patients (Table 2). In these patients, 54 patients (50%) had an eosinophilia cluster, and of these 29 were within 1 month of SJIA diagnosis. Exposure to IL-1 or IL-6 blocking biologics occurred in 73 patients (68%), of which 54 (74%) occurred within 1 month of SJIA diagnosis. Both biologic exposure and eosinophilia occurred in 40 (37%) patients. Eosinophilia in SJIA patients with and without biologic medication exposure was not significantly different (p 0.22). The first eosinophilia cluster occurred before IL-1 or IL-6 blocking biologic exposure in 15 patients (38%) and during or after medication exposure in 25 patients (62.5%). Eosinophilia clusters occurred within 1 month of the first IL-1 or IL-6 blocking biologic exposure in 25 patients, and of these 23 were within 1 month of SJIA diagnosis.

Conclusion: We identified a SJIA cohort in an EHR with extensive longitudinal clinical data and efficiently extracted data to identify eosinophilia and IL-1 and IL-6 blocking biologic exposure. Eosinophilia and biologic medication exposures were common at the time of SJIA diagnosis. Thus far, significant relationships between SJIA patients with IL-1 or IL-6 blocking biologic use and eosinophilia have not been identified. Studies in SJIA subpopulations are needed to determine if eosinophilia varies by clinical characteristics.  

Supporting image 1

Supporting image 2


Disclosures: R. Dickey: None; D. Dhar: None; S. Gangireddy: None; H. Ong: None; W. Wei: None; A. Patrick: None.

To cite this abstract in AMA style:

Dickey R, Dhar D, Gangireddy S, Ong H, Wei W, Patrick A. Eosinophilia and Exposure to IL-1 and IL-6 Blocking Biologic Medications in a Systemic Juvenile Idiopathic Arthritis Patient Cohort [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/eosinophilia-and-exposure-to-il-1-and-il-6-blocking-biologic-medications-in-a-systemic-juvenile-idiopathic-arthritis-patient-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/eosinophilia-and-exposure-to-il-1-and-il-6-blocking-biologic-medications-in-a-systemic-juvenile-idiopathic-arthritis-patient-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology